PHLPP2 variation is associated with prognosis as well as ferroptosis in patients of advanced lung adenocarcinoma harboring EGFR+TP53 co-mutations

doi:10.16352/j.issn.1001-6325.2026.01.0103

Abstract

Abstract: Objective To investigate the relationship between the PHLPP2 and the efficacy of targeted combined chemotherapy as well as ferroptosis in patients with advanced lung adenocarcinoma (LUAD) harboring EGFR+TP53 co-mutations. Methods Data of 98 patients with advanced LUAD with EGFR+TP53 co-mutation treated with targeted combination chemotherapy from August 2018 to August 2023 were reviewed. The PHLPP2 variations were analyzed and divided into poor prognosis group (n=47) and good prognosis group (n=51) according to prognosis. The dose-response relationship between ferroptosis indicators and poor prognosis was analyzed by restricted cubic spline (RCS) model. The levels of ferroptosis indicators in different PHLPP2 mutations and their relationship with poor prognosis were compared. Results PHLPP2 mutation rate was 30.61%, mainly missense mutation and point mutation. Serum ferritin (SF), malondialdehyde (MDA) and reactive oxygen species (ROS) in poor prognosis group were lower than those in good prognosis group (P＜0.05), and glutathione peroxidase 4 (GPX4), glutathione (GSH) and PHLPP2 mutants in poor prognosis group were higher than those in good prognosis group(P＜0.05). The risk of poor prognosis was correlated with SF, GPX4, GSH, MDA and ROS in a nonlinear dose-response relationship (P_{for non linear}＜0.05). SF, MDA and ROS of wild type were higher than those of mutant type (P＜0.05), GPX4 and GSH were lower than those of mutant type (P＜0.05). There were differences in poor prognosis between different PHLPP2 and different ferroptosis indicators (P＜0.05). Conclusions PHLPP2 mutation affects the clinical efficacy of targeted combination chemotherapy in the treatment of advanced LUAD with EGFR+TP53 co-mutation, and is associated with ferroptosis.

Key words: PHLPP2, EGFR+TP53 co-mutation, lung adenocarcinoma, efficacy, ferroptosis

CLC Number:

R734.2

ZHANG Yufeng, ZHANG Xinna, ZHOU Yanjiao. PHLPP2 variation is associated with prognosis as well as ferroptosis in patients of advanced lung adenocarcinoma harboring EGFR+TP53 co-mutations[J]. Basic & Clinical Medicine, 2026, 46(1): 103-108.

References

[1]陈清霞, 梁玉玲, 罗亚兰, 等. 抑制NRF1/ABCC1提高人肺腺癌细胞系对顺铂化学治疗的敏感性[J]. 基础医学与临床, 2025, 45: 51-59.
[2]Ferrara MG, Belluomini L, Smimmo A, et al. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors[J]. Crit Rev Oncol Hematol, 2023, 184: 103929. doi: 10.1016/j.critrevonc.2023.103929.
[3]Tan J, Hu C, Deng P, et al. The predictive values of advanced non-small cell lung cancer patients harboring uncommon EGFR mutations-the mutation patterns, use of different generations of EGFR-TKIS, and concurrent genetic alterations[J]. Front Oncol, 2021, 11: 646577. doi: 10.3389/fonc.2021.646577.
[4]Lordén G, Lam AJ, Levings MK, et al. PHLPP signaling in immune cells[J]. Curr Top Microbiol Immunol, 2022, 436: 117-143.
[5]Hussein NA, Ebid SA, Ahmad MA, et al. The possible correlation between miR-762, Hippo signaling pathway, TWIST1, and SMAD3 in lung cancer and chronic inflammatory diseases[J]. Sci Rep, 2024, 14: 8246. doi: 10.1038/s41598-024-58704-5.
[6]Xia X, Pi W, Chen M, et al. Emerging roles of PHLPP phosphatases in lung cancer[J]. Front Oncol, 2023, 13: 1216131. doi: 10.3389/fonc.2023.1216131.
[7]中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2022版)[J]. 中华医学杂志, 2022, 102: 1706-1740.
[8]Yan Y, Krecke KN, Bapat AS, et al. Phosphatase PHLPP2 regulates the cellular response to metabolic stress through AMPK[J]. Cell Death Dis, 2021, 12: 904. doi: 10.1038/s41419-021-04196-4.
[9]Wang W, Xia X, Chen K, et al. Reduced PHLPP expression leads to EGFR-TKI resistance in lung cancer by activating PI3K-AKT and MAPK-ERK dual signaling[J]. Front Oncol, 2021, 11: 665045. doi: 10.3389/fonc.2021.665045.
[10]王微, 夏鑫杭, 杨海华, 等. 磷酸酶PHLPP2抑制GPX4活性增强非小细胞肺癌铁死亡诱导剂RSL3敏感性的作用分析[J]. 肿瘤学杂志, 2022, 28: 459-464.
[11]Wen Y, Zhang W, Wang D, et al. Propofol ameliorates cognitive deficits following splenectomy in aged rats by inhibiting ferroptosis via the SIRT1/Nrf2/GPX4 pathway[J]. NeuroReport, 2024, 35: 846-856.
[12]Zhang W, Jiang B, Liu Y, et al. Bufotalin induces ferroptosis in non-small cell lung cancer cells by facilitating the ubiquitination and degradation of GPX4[J]. Free Radic Biol Med, 2022, 180: 75-84.

[1]	LIU Tianna, LI Yang, DENG Yudi, WU Fuju. Progress on poly(C)-binding protein 1 in ferroptosis [J]. Basic & Clinical Medicine, 2025, 45(11): 1501-1505.
[2]	LI Wenhua, WANG Runlin, KANG Qianpeng, HUANG Mei, GUO Zhengguang, ZHANG Chunlin, HUANG Yongsheng. p97 inhibitor EerⅠ induces apoptosis and ferroptosis of gastric cancer cell line AGS [J]. Basic & Clinical Medicine, 2025, 45(11): 1401-1408.
[3]	FU Miao, LIU Peng, TIAN Wen, WANG Sha, YIN Xiaomei, LIU Hao, WANG Donghai. METTL3 regulates ferroptosis and malignant progression of cervical cancer cells through mediating TRPM7 methylation [J]. Basic & Clinical Medicine, 2025, 45(10): 1318-1325.
[4]	ZENG Cimei, HUANG Denggao, WANG Lei, LIANG Haimei, MA Ximiao. Silencing LINC00460 inhibits proliferation and migration of human lung adenocarcinoma cell lines via EZH2 [J]. Basic & Clinical Medicine, 2025, 45(10): 1298-1305.
[5]	CHEN Qingxia, LIANG Yuling, LUO Yalan, NIU Bin. Inhibition of NRF1/ABCC1 improves chemosensitivity of human lung adenocarcinoma cell lines to cisplatin [J]. Basic & Clinical Medicine, 2025, 45(1): 51-59.
[6]	XIAO Yanhong, JIANG Mingdong, LIN Yeyuan, RAN Can, LIANG Bo. Scutellarin inhibits proliferation and migration of human prostate cancer cell line PC-3 [J]. Basic & Clinical Medicine, 2024, 44(9): 1229-1235.
[7]	XIAO Yanxin, LIU Yan, XU Lingling, ZHOU Yaru. Research progress on the role of ferroptosis in the pathogenesis of non-alcoholic fatty liver disease [J]. Basic & Clinical Medicine, 2024, 44(2): 260-264.
[8]	. Role of TERT in regulating mitochondrial oxidative stress in diseases [J]. Basic & Clinical Medicine, 2024, 44(10): 1436-1441.
[9]	SUN Lijie, HAO Dandan. Progress of researches on inducing hepatic stellate cell ferroptosis for treatment of liver fibrosis [J]. Basic & Clinical Medicine, 2024, 44(1): 108-113.
[10]	WANG Chunyan, WANG Ping, SONG Longfei, LIU Yongquan, MAN Jun. Effects of lncRNA FEZF1-AS1 on proliferation, migration and invasion through regulating EZH2 of lung interstitial cells [J]. Basic & Clinical Medicine, 2024, 44(1): 43-50.
[11]	PAN Shan, LIN Kengqiang, CHEN Shuxing. Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(9): 1359-1363.
[12]	LI Xiang, LI Ye. Research progress on the interaction between autophagy and ferroptosis in non-alcoholic fatty liver disease [J]. Basic & Clinical Medicine, 2023, 43(8): 1294-1298.
[13]	HAO Dandan, ZHANG Lei, BAI Chunying. Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease [J]. Basic & Clinical Medicine, 2023, 43(8): 1317-1321.
[14]	CHU Xiaoyun, CAI Cheng. Research progress on the mechanism of ferroptosis in neonatal acute lung injury [J]. Basic & Clinical Medicine, 2023, 43(6): 1008-1011.
[15]	YAN Lin, LU Juexiu, LUO Ying, LIU Xianxia. Protective effect of BM-MSCs-derived exosome-mediated ferroptosis against anoxia-reoxygenation injury in rat cardiomyoblastl cell line H9c2 [J]. Basic & Clinical Medicine, 2023, 43(5): 771-776.